[en] BACKGROUND AND OBJECTIVES: To maximize graft-versus-leukemia (GVL) effects while minimizing the risk of graft-versus-host disease (GVHD), we undertook a study of allogeneic CD34-selected peripheral blood stem cell (PBSC) transplantation followed by CD8-depleted donor lymphocyte infusion (DLI). DESIGN AND METHODS: Twenty-four patients with advanced hematologic malignancies were included. PBSC were collected in matched (N=16) or one-mismatch (N=8) related donors and CD34-selected. On day 60, donors donated lymphocytes that were CD8-depleted and separated into 3 aliquots containing 2 x 10(6), 1 x 10(7) and 5 x 10(7) CD3+ cells/kg (patients 1-13) or into 2 aliquots containing 1 x 10(7) and 5 x 10(7) CD3+ cells/kg (patients 14-24). The 1st aliquot was infused on day 60 and the other 1 (2) cryopreserved and infused on days 100 (and 140). RESULTS: An average of 100%, 100% and 84% of the scheduled dose could be administered in DLI 1, 2 and 3, respectively. Although the study group was at very high risk of GVHD, the actuarial incidence of grade II-IV acute GVHD was 28% (13% for HLA-identical siblings) with only 1 patient developing grade III-IV GVHD (after DLI). The actuarial 2-year probability of extensive chronic GVHD was similarly low (13% for all patients and 0% for HLA-identical siblings). Individual cases as well as a 30% relapse rate (0% for standard-risk patients versus 55% for high-risk patients) indicated preservation of the GVL effect. INTERPRETATION AND CONCLUSIONS: We conclude that allogeneic transplantation of CD34-selected PBSC followed by pre-emptive CD8-depleted DLI is feasible with rapid engraftment and minimizes the risk of severe GVHD. Large prospective trials are required to prove that it preserves the GVL effect fully.
Disciplines :
Hematology
Author, co-author :
Baron, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Siquet, Jean
Schaaf-Lafontaine, Nicole ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie biologique et immuno hématologie
Baudoux, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > Thérapie cellulaire
Hermanne, Jean-Philippe
Fillet, Georges ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
English
Title :
Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation.
Buckner C.D., Epstein R.B., Rudolph R.H., Clift R.A., Storb R., Thomas E.D. (2001) Allogeneic marrow engraftment following whole body irradiation in a patient with leukemia. J Hematother Stem Cell Res 10:201-208.
Storb R. (1995) Bone marrow transplantation. Transplant Proc 27:2649-2652.
Storek J., Gooley T., Siadak M., Bensinger W.I., Maloney D.G., Chauncey T.R. (1997) Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 90:4705-4709.
Blaise D., Kuentz M., Fortanier C., Bourhis J.H., Milpied N., Sutton L. (2000) Randomized trial of bone marrow versus lenogastrim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Sociėtė Française de Greffe de Moelle. J Clin Oncol 18:537-546.
Champlin R.E., Schmitz N., Horowitz M.M., Chapuis B., Chopra R., Cornelissen J.J. (2000) Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood , IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT); 95:3702-3709.
Powles R., Mehta J., Kulkarni S., Treleaven J., Millar B., Marsden J. (2000) Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: A randomised trial. Lancet 355:1231-1237.
Vigorito A.C., Comenalli Marques Jr. J.F., Penteado Aranha F.J., Oliveira G.B., Martins Miranda E.C., De Souza C.A. (2001) A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of hematologic malignancies: An update. Haematologica 86:665-666.
Bensinger W.I., Martin P.J., Storer B., Clift R., Forman S.J., Negrin R. (2001) Transplantation of bone marrow as compared with peripheral-blood stem cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344:175-181.
Urbano-Ispizua A., Garcia-Conde J., Brunet S., Hernandez F., Sanz G., Petit J. (1997) High incidence of chronic graft versus host disease after allogeneic peripheral blood progenitor cell transplantation. Haematologica , The Spanish Group of Allo-PBPCT; 82:683-689.
Solano C., Martinez C., Brunet S., Tomas J.F., Urbano-Ispizua A., Zuazu J. (1998) Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Bone Marrow Transplant , Spanish Group of Allo-PBT; 22:1129-1135.
Brown R.A., Adkins D., Khoury H., Vij R., Goodnough L.T., Shenoy S. (1999) Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: Graft-versus-host disease and transplant-related mortality. J Clin Oncol 17:806-812.
Goldman J.M., Gale R.P., Horowitz M.M., Biggs J.C., Champlin R.E., Gluckman E. (1988) Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 108:806-814.
Drobyski W.R. (2000) Evolving strategies to address adverse transplant outcomes associated with T cell depletion. J Hematother Stem Cell Res 9:327-337.
Marmont A.M., Gale R.P., Butturini A., Goldman J.M., Martelli M.F., Prentice H.G. (1989) T-cell depletion in allogeneic bone marrow transplantation: Progress and problems. Haematologica 74:235-248.
Marmont A.M., Horowitz M.M., Gale R.P., Sobocinski K., Ash R.C., Van Bekkum D.W. (1991) T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120-2130.
Gale R.P., Horowitz M.M. (1990) Graft-versus-leukemia in bone marrow transplantation. Bone Marrow Transplant , The Advisory Committee of the International Bone Marrow Transplant Registry; 6(SUPPL. 1):94-97.
Martinez C., Urbano-Ispizua A., Rozman C., Marin P., Rovira M., Sierra J. (1999) Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: Comparison of recipients of positive CD34+ selected grafts with recipients of unmanipulated grafts. Exp Hematol 27:561-568.
Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H.J. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555-562.
Dreger P., Viehmann K., Steinmann J., Eckstein V., Muller-Ruchholtz W., Loffler H. (1995) G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: Comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1. Exp Hematol 23:147-154.
Finke J., Brugger W., Bertz H., Behringer D., Kunzmann R., Weber-Nordt R.M. (1996) Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors. Bone Marrow Transplant 18:1081-1086.
Urbano-Ispizua A., Rozman C., Martinez C., Marin P., Briones J., Rovira M. (1997) Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood. Blood 89:3967-3973.
Urbano-Ispizua A., Brunet S., Solano C., Moraleda J.M., Rovira M., Zuazu J. (2001) Allogeneic transplantation of CD34(+)-selected cells from peripheral blood in patients with myeloid malignancies in early phase: A case control comparison with unmodified peripheral blood transplantation. Bone Marrow Transplant 28:349-354.
Kolb H.J., Schattenberg A., Goldman J.M., Hertenstein B., Jacobsen N., Arcese W. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood , European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia; 86:2041-2050.
Mattel H.J., Saglio G., Gottardi E., Gallamini A., Mordini N., Bacigalupo A. (2001) Persisting molecular remission ten years after donor lymphocyte infusion for hematologic relapse in chronic myeloid leukemia. Haematologica 86:545-546.
Porter D.L. (2001) The graft-versus-tumor potential of allogeneic cell therapy: An update on donor leukocyte infusions and nonmyeloablative allogeneic stem cell transplantation. J Hematother Stem Cell Res 10:465-480.
Baron F., Beguin Y. (2000) Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation. Transfusion 40:468-476.
Baron F., Dresse M.F., Beguin Y. (2000) Donor lymphocyte infusion to eradicate recurrent host hematopoiesis after allogeneic BMT for sickle cell disease. Transfusion 40:1071-1073.
Baron F., Frere P., Fillet G., Beguin Y. (2001) Treatment of leukemia relapse after allogeneic hematopoietic stem cell transplantation by donor lymphocyte infusion and STI-571. Haematologica 86:993-994.
Alyea E. (2000) Adoptive immunotherapy: Insights from donor lymphocyte infusions. Transfusion 40:393-395.
De Rosa G., Pezzullo L., Scarpato N., Selleri C., Lucania A., Rotoli B. (2000) Donor lymphocyte infusion for post-transplant relapse of Hodgkin's lymphoma. Haematologica 85:780-781.
Collins Jr. R.H., Shpilberg O., Drobyski W.R., Porter D.L., Giralt S., Champlin R. (1997) Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433-444.
Mackinnon S., Papadopoulos E.B., Carabasi M.H., Reich L., Collins N.H., Boulad F. (1995) Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261-1268.
Dazzi F., Szydlo R.M., Craddock C., Cross N.C., Kaeda J., Chase A. (2000) Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 95:67-71.
Giralt S., Hester J., Huh Y., Hirsch-Ginsberg C., Rondon G., Seong D. (1995) CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86:4337-4343.
Alyea E.P., Soiffer R.J., Canning C., Neuberg D., Schlossman R., Pickett C. (1998) Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 91:3671-3680.
Roman J., Alvarez M.A., Torres A. (2000) Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation. Haematologica 85:1072-1082.
Kolb H.J., Gunther W., Schumm M., Holler E., Wilmanns W., Thierfelder S. (1997) Adoptive immunotherapy in canine chimeras. Transplantation 63:430-436.
Naparstek E., Or R., Nagler A., Cividalli G., Engelhard D., Aker M. (1995) T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 89:506-515.
Martino R., Martin-Henao G., Sureda A., Altes A., Canals C., Brunet S. (2000) Allogeneic peripheral blood stem cell transplantation with CD34+-cell selection and delayed T-cell add-back in adults. Results of a single center pilot study. Haematologica 85:1165-1171.
Stoppa A.M., Aurran T., Chabannon M., Blaise D. (1998) Feasability of CD34+ selected allogeneic bone marrow transplantation (ABMT) followed after 2 months by prophylactic donor lymphocytes infusion (DLI) in high risk hematologic malignancies. Blood 92(SUPPL. 10).
Przepiorka D., Weisdorf D., Martin P., Klingemann H.G., Beatty P., Hows J. (1995) 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825-828.
Margolis J., Vogelsang G. (2000) Chronic graft-versus-host disease. J Hematother Stem Cell Res 9:339-346.
Van Bockstaele D.R., Peetermans M.E. (1989) 1,3′-Diethyl-4,2′-quinolylthiacyanine iodide as a "thiazole orange" analogue for nucleic acid staining. Cytometry 10:214-216.
Ferrara J.L. (2000) Pathogenesis of acute graft-versus-host disease: Cytokines and cellular effectors. J Hematother Stem Cell Res 9:299-306.
Barrett A.J., Mavroudis D., Tisdale J., Molldrem J., Clave E., Dunbar C. (1998) T-cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 21:543-551.
Ratanatharathorn V., Nash R.A., Przepiorka D., Devine S.M., Klein J.L., Weisdorf D. (1998) Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identicat sibling bone marrow transplantation. Blood 92:2303-2314.
Lee C.K., Gingrich R.D., DeMagalhaes-Silverman M., Hohl R.J., Joyce J.K., Scott S.D. (1999) Prophylactic reinfusion of T cerls for T cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 5:15-27.
Alyea E., Weller E., Schlossman R., Canning C., Webb I., Doss D. (2001) T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: Induction of graft-versus-myeloma effect. Blood 98:934-939.
Morecki S., Slavin S. (2000) Toward amplification of a graft-versus-leukemia effect while minimizing graft-versus-host disease. J Hematother Stem Cell Res 9:355-366.
Barrett J., Childs R. (2000) The benefits of an alloresponse: Graft-versus-tumor. J Hematother Stem Cell Res 9:347-354.
Klingemann H.G. (2001) Cellular therapy of cancer with natural killer cells: Will it ever work?. J Hematother Stem Cell Res 10:23-26.
Marijt W.A., Falkenburg J.H. (2001) Specific T cell therapy in leukemia. J Hematother Stem Cell Res 10:493-500.
Baron F., Beguin Y. (2001) Nonmyeloablative allogeneic hematopoietic stem cell transplantation. J Hematother Stem Cell Res, in press; .
Baron F., Baudoux E., Frere P. (2001) Nonmyeloablative stem cell transplantation (NMSCT) with CD8-depleted or CD34-selected PBSC. J Hematother Stem Cell Res, in press; .
Mackinnon S., Barnett L., Heller G. (1996) Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 17:643-647.
